Abstract
Oxaliplatin-combination treatment has been adopted as a standard adjuvant treatment for high-risk stage II and stage III colorectal cancer. Cerebral venous sinus thrombosis (CVST) is a serious adverse event related to this combination treatment. The benefits of this combination treatment outweigh the risks, yet some physicians are reluctant to resume the treatment after the clot has resolved. The authors reported a case of CVST, and the success in resolving this situation with the use of a secondary prophylaxis, a low-molecular weight heparin. Keywords: Oxaliplatin; Central venous sinus thrombosis; Chemotherapy-induced VTE
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
